Imaging agent developer ImaginAb has been awarded $2.3 million in funding from the U.S. National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program to develop PET diagnostic imaging agents.
ImaginAb said it plans to use the funding over the next two years to further accelerate its prostate and pancreatic oncology program.
ImaginAb is also developing a range of preclinical reagents for use with microPET, microSPECT, and optical imaging systems. The company partners with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products.
